Skip to content
IL

iSERA Lifesciences

534920 BSE
₹143.90

Close ·

P/E
Not meaningful: last twelve months’ earnings are mostly a one-off item
View as Markdown
MCP
Close 4 Nov 2026 ₹143.90 +135.76 +1,668% 1Y
Start ₹8.14

Key Fundamentals

MicrocapIT - SoftwareInformation Technology

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
5.95%
Debt to Equity
0.20
EPS (TTM)
−₹0.07
Book Value
₹35.07
Market Cap
—
P/E (TTM)
Not meaningful: last twelve months’ earnings are mostly a one-off item
P/B
4.10
ROE
6.38%
Dividend Yield
0.00%
EBITDA
₹50.00 L
52W High
₹151.05
52W Low
₹8.14

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

51 Average

Data confidence 91/100

Category scores

Quality
35
Poor
Returns, margins, earnings quality 22% weight
Valuation
26
Poor
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
51
Average
Solvency, leverage, coverage 9% weight
Momentum
99
Strong
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

3
  • Stock is trading at 14.7 times its book value
  • Company has high debtors of 337 days.
  • Promoter holding has decreased over last 3 years: -41.4%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallNeutral676
OscillatorsNeutral171
Moving AveragesNeutral505

Key readings

RSI (14)
54.14
Neutral
MACD (12,26,9)
0.22
Bearish
SMA (50)
144.04
Bearish
SMA (200)
79.50
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y−25.74%
5Y−9.40%
3YZero base
1Y+381.48%
TTMZero base

Net profit

Net profit growth by window
10YTurned to profit
5Y−31.94%
3YTurned to profit
1Y+116.67%
TTMTurned to loss

Operating cash flow

Operating cash flow growth by window
10YTurned negative
5YTurned negative
3YOutflow widened by ₹5.23 Cr
1YOutflow widened by ₹3.95 Cr
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+19.36 pp
5Y−70.31 pp
3YNo sales
1Y−31.08 pp
TTMNo sales

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹21.36 Cr
Mar 2018₹28.92 Cr
Mar 2019₹12.30 Cr
Mar 2020₹2.13 Cr
Mar 2021₹2.13 Cr
Mar 2022₹0.00 Cr
Mar 2023₹0.00 Cr
Mar 2024₹0.00 Cr
Mar 2025₹0.27 Cr
Mar 2026₹1.30 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹0.00 Cr
Mar 2018₹0.04 Cr
Mar 2019−₹0.02 Cr
Mar 2020−₹0.42 Cr
Mar 2021₹1.78 Cr
Mar 2022−₹0.11 Cr
Mar 2023−₹0.11 Cr
Mar 2024−₹0.09 Cr
Mar 2025₹0.12 Cr
Mar 2026₹0.26 Cr

Quarterly Results

₹ Cr
534920 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0
0
0
0
0
0
0
0
0
0
0.19
1.16
0
Expenses
0.01
0.02
0.01
0.07
0.01
0.01
0.07
0.04
0.02
0
0.47
0.59
0.34
Operating Profit
−0.01
−0.02
−0.01
−0.07
−0.01
−0.01
−0.07
−0.04
−0.02
0
−0.28
0.57
−0.34
OPM %
—
—
—
—
—
—
—
—
—
—
−147.37%
49.14%
—
Other Income
0
0
0
0
0
0
0
0.27
0
0.01
0
0.06
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
−0.01
−0.02
−0.01
−0.07
−0.01
−0.01
−0.07
0.23
−0.02
0.01
−0.28
0.63
−0.34
Tax %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
12.7%
0%
Net Profit
−0.01
−0.02
−0.01
−0.07
−0.01
−0.01
−0.07
0.23
−0.02
0.01
−0.28
0.55
−0.34
EPS (₹)
0
0
0
−0.08
−0.01
−0.01
−0.08
0.27
−0.02
0.01
−0.33
0.65
−0.4

Profit & Loss

₹ Cr
534920 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
10.9
25.5
21.36
28.92
12.3
2.13
2.13
0
0
0
0.27
1.3
1.35
Expenses
10.28
25.14
20.92
28.46
11.98
2.19
0.19
0.11
0.11
0.09
0.13
1.03
1.4
Operating Profit
0.62
0.36
0.44
0.46
0.32
−0.06
1.94
−0.11
−0.11
−0.09
0.14
0.27
−0.05
OPM %
5.69%
1.41%
2.06%
1.59%
2.6%
−2.82%
91.08%
—
—
—
51.85%
20.77%
−3.7%
Other Income
0
−12.61
0
0
0
0
0
0
0
0
0
0.07
0.07
Interest
0
0.16
0.2
0.27
0.23
0.22
0.02
0
0
0
0
0
0
Depreciation
0.5
0.08
0.21
0.15
0.08
0.12
0.12
0
0
0
0
0
0
PBT
0.12
−12.49
0.03
0.04
0.01
−0.4
1.8
−0.11
−0.11
−0.09
0.14
0.34
0.02
Tax %
0%
0.4%
100%
25%
200%
5%
1.11%
0%
0%
0%
14.29%
23.53%
—
Net Profit
0.12
−12.54
0
0.04
−0.02
−0.42
1.78
−0.11
−0.11
−0.09
0.12
0.26
−0.06
EPS (₹)
0
−0.46
0
0
0
−0.02
0.06
0
0
−0.11
0.14
0.31
−0.07
Div. Payout %
0%
0%
—
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
534920 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
10.6
10.6
10.6
10.6
10.6
10.6
10.6
0.3
0.3
0.32
0.32
8.41
Reserves
2.44
−10.1
−10.09
−10.05
−10.07
−10.49
−10.71
−0.31
−0.42
−0.54
−0.42
−0.16
Borrowings
4.97
6.15
6.83
7.49
7.53
6.56
2.02
0
0.13
0.18
1.61
1.66
Other Liabilities
2.54
4.61
5.57
8.19
4.12
3.81
2.59
0.02
0.04
0.1
0.05
0.65
Total Liabilities
20.55
11.26
12.91
16.23
12.18
10.48
4.5
0.01
0.05
0.06
1.56
10.56
Fixed Assets
6.65
0.48
0.44
0.45
0.75
0.62
0.43
0
0
0
0
0
CWIP
1.96
0
0
0
0
0
0
0
0
0
0
0
Investments
4.2
0
0
0
0
0
0
0
0
0
0
0
Other Assets
7.74
10.78
12.47
15.78
11.43
9.86
4.07
0.01
0.05
0.06
1.56
10.56
Total Assets
20.55
11.26
12.91
16.23
12.18
10.48
4.5
0.01
0.05
0.06
1.56
10.56

Cash Flow

₹ Cr
534920 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0.5
0.81
−0.63
−0.51
0.34
0.97
4.45
−0.3
−0.12
−0.06
−1.4
−5.35
Investing
−1.16
−0.4
−0.16
−0.16
−0.38
0
0.1
0
0
0
0
0.06
Financing
0.69
−0.42
0.77
0.66
0.04
−0.97
−4.55
0.3
0.13
0.06
1.42
8.14
Net Cash Flow
0.04
−0.01
−0.02
−0.01
0
0
−0.01
0
0
0
0.02
2.85
Free Cash Flow
−0.78
0.41
−0.79
−0.67
−0.04
0.97
4.55
−0.3
−0.12
−0.06
−1.4
−5.35
CFO/OP
81
225
−143
−109
112
−1,650
229
273
109
67
−986
−1,952

Ratios

534920 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
193
123
175
178
297
1,470
499
—
—
—
419
337
Inventory Days
—
—
0
0
0
0
—
—
—
—
—
—
Cash Conversion Cycle
193
123
175
178
297
1,470
499
—
—
—
419
337
Working Capital Days
174
65.13
91.59
73.58
170
1,042
260
—
—
—
351
225
ROCE %
0.68%
2.27%
3.29%
4.03%
2.98%
−2.44%
42.42%
−11.58%
—
—
19.05%
5.95%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view iSERA Lifesciences insights

54 extracted metrics across FY08–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 55.07%
  • Public 44.92%
  • FIIs 0.01%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about iSERA Lifesciences

What does iSERA Lifesciences Ltd do?
Incorporated in 1993, Covidh Technologies Ltd is engaged in IT/ITES business.
Where is iSERA Lifesciences Ltd (ISERA) listed?
iSERA Lifesciences Ltd trades under code 534920 on the BSE.
Which sector does iSERA Lifesciences Ltd belong to?
iSERA Lifesciences Ltd is classified under the Information Technology sector, in the Computer Software & Consulting industry.
What is the 52-week high and low of iSERA Lifesciences Ltd?
Over the last 52 weeks iSERA Lifesciences Ltd has traded between ₹8.14 and ₹151.05 as of 4 Nov 2026.
What is the Return on Equity (ROE) of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd reported a return on equity of 6.38%. Its debt-to-equity ratio is 0.20.

Company Information

Incorporated in 1993, Covidh Technologies Ltd is engaged in IT/ITES business.

Website covidh.co.in
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/534920.md for iSERA Lifesciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More IT Software stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month